Last reviewed · How we verify
ε-Aminocaproic Acid (EACA)
ε-Aminocaproic Acid (EACA) is an antifibrinolytic agent used to prevent and treat bleeding by inhibiting the breakdown of blood clots. It is primarily used in surgical settings and for conditions where excessive bleeding is a concern. EACA is not approved by the FDA but is used off-label for various indications. The drug has a relatively low risk profile but can cause side effects such as nausea, vomiting, and dizziness. Its use requires careful monitoring, especially in patients with renal impairment or those at risk of thrombosis.
At a glance
| Generic name | ε-Aminocaproic Acid (EACA) |
|---|---|
| Also known as | Amicar |
| Sponsor | Miller Orthopedic Specialists |
| Drug class | Antifibrinolytic |
| Target | Plasminogen and plasmin |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Other anticoagulants
Key clinical trials
- Efficacy of Amicar for Children Having Craniofacial Surgery (PHASE2)
- Management of Intracerebral Hemorrhage With Aminocaproic Acid - Pilot Study (PHASE1)
- Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ε-Aminocaproic Acid (EACA) CI brief — competitive landscape report
- ε-Aminocaproic Acid (EACA) updates RSS · CI watch RSS
- Miller Orthopedic Specialists portfolio CI